CClinicalTrials.gg
TerminatedNCT02663934Ex/HIVUpdated Nov 21, 2023Results posted

Exercise Training to Improve Brain Health in Older HIV+ Individuals

An interventional study of Exercise and Stretching and Social Interaction in HIV, sponsored by Washington University School of Medicine. Terminated at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2023-11-21.

Sponsored by Washington University School of Medicine · Not applicable, Interventional, and Treatment

Why this study was terminated
COVID-19 Risk
Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

Management and treatment of older persons living with HIV (PLWH) (≥ 40 years old) is becoming increasingly more complex as a majority is greater than 40 years old. This proposal will conduct a prospective controlled intervention trial to assess the quantitative and qualitative effects of a monitored aerobic/resistance exercise (EXS) program compared to a social-interaction stretching (SIS) program on brain health (neuropsychological performance testing and neuroimaging measurements) in older PLWH. These results could influence public health policy by encouraging PLWH to adopt a more physically active lifestyle and stimulate the development of effective EXS programs for older PLWH.

Read the detailed description

Management of older persons living with HIV (PLWH) (≥ 40 years old) is becoming increasingly more complex as a majority is greater than 40 years old. Attempts to improve the quality of life of older PLWH using adjunctive therapeutics to combination antiretroviral therapy (cART) have largely been unsuccessful.

While the impact of physical activity on brain health (assessed by neuropsychological performance and neuroimaging) has been well studied in older healthy HIV uninfected (HIV-) individuals and neurodegenerative conditions, few studies have concentrated on older PLWH. Both clinically and pathophysiologically, HIV associated neurocognitive disorders (HAND) differs from other neurodegenerative disorders seen with aging (e.g. Alzheimer's disease (AD). A positive association relationship between exercise and cognition has been observed in PLWH, but physical activity has been primarily examined using self-report questionnaires that are subjective and not quantitative. To date, no study has focused on the direct effects of exercise on neuropsychological performance or neuroimaging in PLWH.

The objective of this proposal is to conduct a prospective controlled intervention trial to determine if an increase in physical activity through a monitored aerobic and resistance exercise (EXS) program improves brain health in older PLWH. We will quantify physical function (physical activity using cardiorespiratory capacity and actigraphy) and brain function [neuropsychological performance testing and neuroimaging (cerebral blood flow (CBF) and brain volume)] in older physically inactive PLWH at baseline and 26 weeks after randomization to either an EXS or a social-interaction stretching (SIS) program. In addition, we will obtain stool samples, serum markers of neurogenesis, glucose regulation, and systemic inflammation.

A direct impact of these expected outcomes will be the adoption of a more physically active lifestyle by older PLWH and improved EXS guidelines and programs for older PLWH.

02

Conditions studied

  • HIV

Keywords

  • HIV, AIDS, Cognition, Memory, Exercise, Stretching
03

In context

Lead sponsor

Washington University School of Medicine is the lead sponsor of 1,765 studies on the registry; 271 are open to participants now.

Of its 324 completed or terminated interventional studies of FDA-regulated products, 212 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. age > 40 years old
  2. documented history of HIV infection
  3. on stable combination antiretroviral therapy (cART) for approximately 3 months with undetectable plasma HIV RNA
  4. physically inactive-sedentary lifestyle (approximately \<2 hours of exercise/week) and not engaged in regular exercise for approximately 3 months prior to enrollment
  5. approximately 9 years of education
  6. able to have an MRI
  7. able to provide written informed consent (does not have LAR, POA, etc.)

Exclusion criteria

Exclusion Criteria:

  1. approximately >2x/week of moderate (or greater) exercise
  2. cardiovascular/cerebrovascular disease or pulmonary disease that precludes ability to safely exercise
  3. significant neurological disorders (e.g. stroke, head injury with loss of consciousness for >30 minutes, developmental learning disability
  4. presence of dementia or behavioral disorders that would prevent ability to follow the protocol
  5. alcohol or substance abuse/ dependence within the last 6 months (DSM-4 TR)
  6. contraindications to MRI scanning (e.g. claustrophobia, pacemaker)
  7. pregnant or breast-feeding
  8. unable to provide written informed consent
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Exercise (EXS)

    All EXS sessions will be at an exercise facility at the WUSTL medical campus. Sessions will be offered weekdays. Each session will start with range of motion exercises. Participants will follow an individualized exercise training prescription based on baseline cardiovascular testing. Individual aerobic exercise intensity is based on % of maximum heart rate achieved during the baseline cardiorespiratory fitness test. The target exercise HR will start at 50% and progress to 85% HR reserve. During aerobic exercise, a battery-operated HR monitor will monitor HR. Exercise intensity \& duration will be increased as the participant acclimates to the exercise prescription. Adaptation is determined when a given exercise intensity yields a lower HR than prior sessions conducted at the same intensity.

    Behavioral: Exercise

  • Active comparator
    Social Interaction Stretching (SIS)

    This group will serve as a control group against which to gauge the effects of aerobic and resistance training on cognitive function. Participants in this group will follow the same schedule and format as the EXS group. These participants will be supervised by the same trainer and will receive the same amount of attention and class interaction as participants in the EXS program. These SIS participants will receive instructions on stretching, range of motion, limbering, and toning; but the intensity will be far less than that achieved in the EXS classes. Activities will focus on flexibility enhancement. As the participant's level of flexibility increases, stretches with increasing levels of difficulty will be incorporated into the program.

    Behavioral: Stretching and Social Interaction

Interventions

  • BehavioralExercise

    The resistance exercise training component will follow aerobic exercise and will consist of 4 upper and 3 lower body routines. A combination of guided-motion machines and free weights will be used. Voluntary maximum strength will be measured during the first 4 sessions on each exercise station. The program will initially consist of 1-2 sets of each exercise while lifting a weight that causes muscle fatigue after 8-10 repetitions. The trainer will monitor each participant's exercise response, and when the participant can comfortably lift the weight for 12 repetitions on any exercise, the weight will be increased to cause the muscle group to fatigue after 8 repetitions. This progressive 8-12 repetition cycle is repeated for each exercise over 26 weeks.

  • BehavioralStretching and Social Interaction

    Participants will receive instructions on stretching, range of motion, limbering, and toning. Activities will focus on flexibility enhancement. Along with the stretching and flexibility, this group will have a social interaction component. They will have discussions and interact with trainers and coordinators during all their sessions. These participants will be supervised by the same trainer and will receive the same amount of attention and class interaction as participants in the EXS program.

06

What researchers measure

Primary outcomes

  1. Change in Global Cognition From Baseline to Follow up, in Exercise Group vs. Stretching Group

    This measure examines the global z-score which is an average of all the individual cognitive test z scores. We looked at changes in global Z-scores from baseline to follow-up (6 months). A Z-score of 0 represents the population mean. Z-scores are considered to be better when they are above the mean and represent a better outcome.

    Time frame: 6 months

  2. Changes in Brain Structural/Functional Measures in Older PLWH

    The Investigators will assess if an EXS program improves brain structure and function more than a SIS program in older sedentary PLWH. Changes in brain volumetrics (total cortex volume) at baseline (BL) and 26 weeks will be compared between EXS and SIS groups.

    Time frame: 26 weeks

  3. Change in Level of Daily Activity

    Investigators will examine the amount of change in daily activity based on 7-day actigraphy at baseline and then again at follow-up (26 weeks later). Daily activity is measured using an actigraph that participants wear on their wrist and it measures the amount of time spent in sedentary, slightly active, moderately active, vigorously active or very vigorously active categories.

    Time frame: 6 Months

07

Results

Posted Nov 21, 2023

Participant flow

Participants were recruited from local clinics as well as a participant registry. Recruitment started in July of 2015 and concluded in November of 2020. There was a pause in recruitment due to the COVID-19 Pandemic from March 2020 through August 2020, and then was terminated early due to a rise in cases in our area in November 2020. A total of 462 were initially screened for the study \& 75 were initially enrolled in the study. Out of those 75, a total of 65 were randomized into the intervention.

Participant flow — Overall Study
MilestoneExercise (EXS)Social Interaction Stretching (SIS)
Started4520
Completed3314
Not completed126

Outcome measures

PrimaryChange in Global Cognition From Baseline to Follow up, in Exercise Group vs. Stretching Group

This measure examines the global z-score which is an average of all the individual cognitive test z scores. We looked at changes in global Z-scores from baseline to follow-up (6 months). A Z-score of 0 represents the population mean. Z-scores are considered to be better when they are above the mean and represent a better outcome.

Time frame:
6 months
Reported as:
Mean · z-score
Change in Global Cognition From Baseline to Follow up, in Exercise Group vs. Stretching Group
z-scoreExercise (EXS)Social Interaction Stretching (SIS)
Change in Global Cognition From Baseline to Follow up, in Exercise Group vs. Stretching Group.10 ± .29.20 ± .33
Statistical analysis
  • Exercise (EXS) vs Social Interaction Stretching (SIS) · ANOVA · p = 0.31 · Mean difference (net): 0.15 · 95% CI .05 to .25
PrimaryChanges in Brain Structural/Functional Measures in Older PLWH

The Investigators will assess if an EXS program improves brain structure and function more than a SIS program in older sedentary PLWH. Changes in brain volumetrics (total cortex volume) at baseline (BL) and 26 weeks will be compared between EXS and SIS groups.

Time frame:
26 weeks
Reported as:
Mean · mm^3
Changes in Brain Structural/Functional Measures in Older PLWH
mm^3Exercise (EXS)Social Interaction Stretching (SIS)
Changes in Brain Structural/Functional Measures in Older PLWH-546.1 ± 10358366.6 ± 8102
Statistical analysis
  • Exercise (EXS) vs Social Interaction Stretching (SIS) · ANOVA · p = .24 · Mean difference (net): 1.42
  • Exercise (EXS) · Regression, Linear · p = .02 · Slope: 0.41
  • Exercise (EXS) · Regression, Linear · p = 0.02 · Slope: 0.40
PrimaryChange in Level of Daily Activity

Investigators will examine the amount of change in daily activity based on 7-day actigraphy at baseline and then again at follow-up (26 weeks later). Daily activity is measured using an actigraph that participants wear on their wrist and it measures the amount of time spent in sedentary, slightly active, moderately active, vigorously active or very vigorously active categories.

Time frame:
6 Months
Reported as:
Mean · Average Minutes per Day
Change in Level of Daily Activity
Average Minutes per DayExercise (EXS)Social Interaction Stretching (SIS)
Change in Level of Daily Activity-23.9 ± 114.8-5.3 ± 98.9
Statistical analysis
  • Exercise (EXS) · Regression, Linear · p = .005 · Slope: .47

Adverse events

Collected over Through study completion, an average of approximately 6 months per participant.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Exercise (EXS)0/45 (0%)0/45 (0%)0/45 (0%)
Social Interaction Stretching (SIS)0/20 (0%)0/20 (0%)0/20 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Exercise (EXS)Social Interaction Stretching (SIS)Total
Mean56.5 (41 to 70)56.5 (50 to 71)56.5 (41 to 71)
Sex: Female, Male
Sex: Female, Male(Participants)Exercise (EXS)Social Interaction Stretching (SIS)Total
Female13215
Male321850
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Exercise (EXS)Social Interaction Stretching (SIS)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American291443
White16622
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Exercise (EXS)Social Interaction Stretching (SIS)Total
United States452065
Education
Education(years)Exercise (EXS)Social Interaction Stretching (SIS)Total
Mean12.9 ± 2.413.9 ± 2.213.2 ± 2.4
Body Mass Index
Body Mass Index(kg/m^2)Exercise (EXS)Social Interaction Stretching (SIS)Total
Mean30.5 ± 7.028.9 ± 5.729.7 ± 6.6
Viral Load Undetectable (<50 copies/mL)
Viral Load Undetectable (<50 copies/mL)(Participants)Exercise (EXS)Social Interaction Stretching (SIS)Total
Count of participants452065
Median recent CD4 T-cell count (cells/mm3) (IQR)
Median recent CD4 T-cell count (cells/mm3) (IQR)(cells/mm3)Exercise (EXS)Social Interaction Stretching (SIS)Total
Median581 (474 to 817)561 (362 to 771)578 (450 to 789)

3 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Washington University in St. Louis
    Saint Louis, Missouri 63110, United States
09

References and documents

Publications

  • Spudich S. HIV and neurocognitive dysfunction. Curr HIV/AIDS Rep. 2013 Sep;10(3):235-43. doi: 10.1007/s11904-013-0171-y. PubMed 23860944 ↗
  • Spudich S, Gonzalez-Scarano F. HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. Cold Spring Harb Perspect Med. 2012 Jun;2(6):a007120. doi: 10.1101/cshperspect.a007120. PubMed 22675662 ↗
  • Clifford DB, Ances BM. HIV-associated neurocognitive disorder. Lancet Infect Dis. 2013 Nov;13(11):976-86. doi: 10.1016/S1473-3099(13)70269-X. PubMed 24156898 ↗
  • Shah S, Mildvan D. HIV and aging. Curr Infect Dis Rep. 2006 May;8(3):241-7. doi: 10.1007/s11908-006-0065-x. PubMed 16643776 ↗
  • Valcour V, Paul R. HIV infection and dementia in older adults. Clin Infect Dis. 2006 May 15;42(10):1449-54. doi: 10.1086/503565. Epub 2006 Apr 13. PubMed 16619159 ↗
  • Hall HI, Song R, Rhodes P, Prejean J, An Q, Lee LM, Karon J, Brookmeyer R, Kaplan EH, McKenna MT, Janssen RS; HIV Incidence Surveillance Group. Estimation of HIV incidence in the United States. JAMA. 2008 Aug 6;300(5):520-9. doi: 10.1001/jama.300.5.520. PubMed 18677024 ↗
  • Ortega M, Ances BM. Role of HIV in amyloid metabolism. J Neuroimmune Pharmacol. 2014 Sep;9(4):483-91. doi: 10.1007/s11481-014-9546-0. Epub 2014 May 10. PubMed 24816714 ↗
  • Xu J, Ikezu T. The comorbidity of HIV-associated neurocognitive disorders and Alzheimer's disease: a foreseeable medical challenge in post-HAART era. J Neuroimmune Pharmacol. 2009 Jun;4(2):200-12. doi: 10.1007/s11481-008-9136-0. Epub 2008 Nov 19. PubMed 19016329 ↗
  • Cohen RA, Seider TR, Navia B. HIV effects on age-associated neurocognitive dysfunction: premature cognitive aging or neurodegenerative disease? Alzheimers Res Ther. 2015 Apr 6;7(1):37. doi: 10.1186/s13195-015-0123-4. eCollection 2015. PubMed 25848401 ↗
  • Desquilbet L, Jacobson LP, Fried LP, Phair JP, Jamieson BD, Holloway M, Margolick JB. A frailty-related phenotype before HAART initiation as an independent risk factor for AIDS or death after HAART among HIV-infected men. J Gerontol A Biol Sci Med Sci. 2011 Sep;66(9):1030-8. doi: 10.1093/gerona/glr097. Epub 2011 Jun 30. PubMed 21719610 ↗
  • Justice AC. HIV and aging: time for a new paradigm. Curr HIV/AIDS Rep. 2010 May;7(2):69-76. doi: 10.1007/s11904-010-0041-9. PubMed 20425560 ↗
  • Justice AC, McGinnis KA, Skanderson M, Chang CC, Gibert CL, Goetz MB, Rimland D, Rodriguez-Barradas MC, Oursler KK, Brown ST, Braithwaite RS, May M, Covinsky KE, Roberts MS, Fultz SL, Bryant KJ; VACS Project Team. Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkers. HIV Med. 2010 Feb;11(2):143-51. doi: 10.1111/j.1468-1293.2009.00757.x. Epub 2009 Sep 14. PubMed 19751364 ↗
  • Onen NF, Agbebi A, Shacham E, Stamm KE, Onen AR, Overton ET. Frailty among HIV-infected persons in an urban outpatient care setting. J Infect. 2009 Nov;59(5):346-52. doi: 10.1016/j.jinf.2009.08.008. Epub 2009 Aug 23. PubMed 19706308 ↗
  • Casau NC. Perspective on HIV infection and aging: emerging research on the horizon. Clin Infect Dis. 2005 Sep 15;41(6):855-63. doi: 10.1086/432797. Epub 2005 Jul 28. PubMed 16107986 ↗
  • Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R, Backman L, Hanninen T, Jula A, Laatikainen T, Lindstrom J, Mangialasche F, Paajanen T, Pajala S, Peltonen M, Rauramaa R, Stigsdotter-Neely A, Strandberg T, Tuomilehto J, Soininen H, Kivipelto M. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015 Jun 6;385(9984):2255-63. doi: 10.1016/S0140-6736(15)60461-5. Epub 2015 Mar 12. PubMed 25771249 ↗
  • Baker LD, Frank LL, Foster-Schubert K, Green PS, Wilkinson CW, McTiernan A, Cholerton BA, Plymate SR, Fishel MA, Watson GS, Duncan GE, Mehta PD, Craft S. Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimer's disease. J Alzheimers Dis. 2010;22(2):569-79. doi: 10.3233/JAD-2010-100768. PubMed 20847403 ↗
  • Damirchi A, Tehrani BS, Alamdari KA, Babaei P. Influence of aerobic training and detraining on serum BDNF, insulin resistance, and metabolic risk factors in middle-aged men diagnosed with metabolic syndrome. Clin J Sport Med. 2014 Nov;24(6):513-8. doi: 10.1097/JSM.0000000000000082. PubMed 24662570 ↗
  • Balsamo S, Willardson JM, Frederico Sde S, Prestes J, Balsamo DC, Dahan da CN, Dos Santos-Neto L, Nobrega OT. Effectiveness of exercise on cognitive impairment and Alzheimer's disease. Int J Gen Med. 2013 May 24;6:387-91. doi: 10.2147/IJGM.S35315. Print 2013. PubMed 23737675 ↗
  • Rao AK, Chou A, Bursley B, Smulofsky J, Jezequel J. Systematic review of the effects of exercise on activities of daily living in people with Alzheimer's disease. Am J Occup Ther. 2014 Jan-Feb;68(1):50-6. doi: 10.5014/ajot.2014.009035. PubMed 24367955 ↗
  • Walker JM, Klakotskaia D, Ajit D, Weisman GA, Wood WG, Sun GY, Serfozo P, Simonyi A, Schachtman TR. Beneficial effects of dietary EGCG and voluntary exercise on behavior in an Alzheimer's disease mouse model. J Alzheimers Dis. 2015;44(2):561-72. doi: 10.3233/JAD-140981. PubMed 25318545 ↗
  • Dufour CA, Marquine MJ, Fazeli PL, Henry BL, Ellis RJ, Grant I, Moore DJ; HNRP Group. Physical exercise is associated with less neurocognitive impairment among HIV-infected adults. J Neurovirol. 2013 Oct;19(5):410-7. doi: 10.1007/s13365-013-0184-8. Epub 2013 Aug 10. PubMed 23934585 ↗
  • Fazeli PL, Woods SP, Heaton RK, Umlauf A, Gouaux B, Rosario D, Moore RC, Grant I, Moore DJ; HNRP Group. An active lifestyle is associated with better neurocognitive functioning in adults living with HIV infection. J Neurovirol. 2014 Jun;20(3):233-42. doi: 10.1007/s13365-014-0240-z. Epub 2014 Feb 20. PubMed 24554483 ↗
  • Fillipas S, Oldmeadow LB, Bailey MJ, Cherry CL. A six-month, supervised, aerobic and resistance exercise program improves self-efficacy in people with human immunodeficiency virus: a randomised controlled trial. Aust J Physiother. 2006;52(3):185-90. doi: 10.1016/s0004-9514(06)70027-7. PubMed 16942453 ↗
  • Mapstone M, Hilton TN, Yang H, Guido JJ, Luque AE, Hall WJ, Dewhurst S, Shah K. Poor Aerobic Fitness May Contribute to Cognitive Decline in HIV-infected Older Adults. Aging Dis. 2013 Aug 27;4(6):311-9. doi: 10.14336/AD.2013.0400311. eCollection 2013. PubMed 24307964 ↗
  • Mattson MP. Exercise and the brain: a slap on the HAND. J Neurovirol. 2013 Oct;19(5):407-9. doi: 10.1007/s13365-013-0208-4. Epub 2013 Sep 27. No abstract available. PubMed 24072548 ↗
  • Rodrigues AM, O'Brien N, French DP, Glidewell L, Sniehotta FF. The question-behavior effect: genuine effect or spurious phenomenon? A systematic review of randomized controlled trials with meta-analyses. Health Psychol. 2015 Jan;34(1):61-78. doi: 10.1037/hea0000104. Epub 2014 Aug 18. PubMed 25133835 ↗
  • Gill AJ, Kolson DL. Chronic inflammation and the role for cofactors (hepatitis C, drug abuse, antiretroviral drug toxicity, aging) in HAND persistence. Curr HIV/AIDS Rep. 2014 Sep;11(3):325-35. doi: 10.1007/s11904-014-0210-3. PubMed 24929842 ↗
  • Rosenfield PL. The potential of transdisciplinary research for sustaining and extending linkages between the health and social sciences. Soc Sci Med. 1992 Dec;35(11):1343-57. doi: 10.1016/0277-9536(92)90038-r. PubMed 1462174 ↗
  • Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, Tunis S, Bergel E, Harvey I, Magid DJ, Chalkidou K. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. CMAJ. 2009 May 12;180(10):E47-57. doi: 10.1503/cmaj.090523. Epub 2009 Apr 16. No abstract available. PubMed 19372436 ↗
  • Masters MC, Ances BM. Role of neuroimaging in HIV-associated neurocognitive disorders. Semin Neurol. 2014 Feb;34(1):89-102. doi: 10.1055/s-0034-1372346. Epub 2014 Apr 8. PubMed 24715492 ↗

Study documents

  • Protocol and statistical analysis plan · Apr 7, 2020
  • Informed consent form · Jul 23, 2020

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided — Data will be shared when the study has closed.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02663934
Lead sponsor
Washington University School of Medicine
Collaborators
University of Missouri, St. Louis, University of California, San Diego
Responsible party
Sponsor
First posted
Jan 26, 2016
Start date
Aug 2016
Primary completion
Nov 30, 2020
Completion
Nov 30, 2020
Results posted
Nov 21, 2023
Last update
Nov 21, 2023

Study contacts

Beau M Ances, MD,PhD
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion